Andere Sprachen Petros Pharmaceuticals, Inc.

Aktien

A3D2B6

US71678J2096

PTPI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 05.07.2024			% 5 Tage	% 1. Jan.
0.415 ^USD	-2.15%		-9.29%	-70.57%

29.05.	Petros Pharmaceuticals schliesst erfolgreich eine KI-integrierte formative Studie zu den menschlichen Faktoren ab, die eine positive Interaktion mit der fur den OTC-Zugang zu STENDRA(R) (avanafil) konzipierten Web-App belegt	CI
15.05.	Petros Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA OTC Switch	30.05.
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) OTC Switch	29.05.
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	14.05.
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	14.05.
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication	14.05.
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals	14.05.
Lemonaid Health, Inc. Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals	14.05.
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health	25.04.
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA through New Agreement with Lemonaid Health	24.04.
Petros, Lemonaid Health Collaborate to Expand Stendra Availability	23.04.
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health	23.04.
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process	16.04.
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)	16.04.
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status	02.04.
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc	11.03.
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider	14.02.
Thinking about buying stock in Helius Medical Technologies, Peraso, GDS Holdings, Everbridge, or Petros Pharmaceuticals?	06.02.
Top Premarket Gainers	30.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Petros Pharmaceuticals, Inc.

Aktien

A3D2B6

US71678J2096

PTPI

Andere Sprachen

Filter